ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Coronavirus

Rohto to start trials for stem cell coronavirus remedy in August

Non-vaccine treatment for ventilator patients due for release after 2021

Rohto Pharmaceutical will test its coronavirus treatment on six patients on ventilators.

OSAKA -- Japan's Rohto Pharmaceutical said Tuesday it plans to launch clinical trials in August for a stem cell-based treatment for patients suffering severe symptoms induced by the novel coronavirus.

The Osaka-based drugmaker looks to verify the safety and effectiveness of the remedy by December 2021 when the tests will close, then quickly put it on the market.

The trials will target COVID-19 patients who have been put on ventilators due to pneumonia-like symptoms. Such a critical state can lead to a complication known as a cytokine storm -- a deleterious autoimmune response to the respiratory virus.

Each patient will receive about 100 million mesenchymal stem cells per dose, which will be administered intravenously. The stem cells, which are found in bone marrow and umbilical cords, are expected to arrive at the affected areas of the lungs where they will suppress the inflammation and the autoimmune response.

Six patients, mainly from Osaka University Hospital, will take part in the trials. Rohto will administer four doses of stem cells to each subject, then observe the effectiveness over two months.

Rohto has developed equipment that automatically cultures mesenchymal stem cells initially harvested from a donor's fatty tissue. The technology is capable of growing roughly 180 billion stem cells over a year, enough to treat about 450 people.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media